\-\ Texto\\:\\ \ \(0\)\
\-\ none\\ available\ \(6\)\
\-\ no\\ treatments\\ have\\ been\\ found\\ that\\ slow\\ the\\ progression\\ of\\ cyst\\ development\\ in\\ adpkd\\.\\ treatments\\ target\\ associated\\ complications\\,\\ such\\ as\\ antihypertensive\\ therapy\\ \\(ace\\ inhibitors\\ or\\ arbs\\)\\ for\\ elevated\\ blood\\ pressure\\,\\ slowing\\ development\\ of\\ left\\ ventricular\\ hypertrophy\\,\\ and\\ preserving\\ renal\\ function\\,\\(1\\)\\ and\\ identification\\ and\\ treatment\\ of\\ possible\\ uti\\ and\\ nephrolithiasis\\.\\ follow\\-up\\ includes\\ us\\ of\\ the\\ kidneys\\ every\\ 1\\-2\\ years\\.\\(2\\)\ \(0\)\
\-\ \\â\\€\\¢\\ ct\\ stone\\ protocol\\:\\ numerous\\ liver\\ and\\ bilateral\\ renal\\ cysts\\ of\\ varying\\ sizes\\ and\\ small\\ renal\\ calcifications\\.\\ \ \(0\)\
\-\ \\â\\€\\¢\\ mra\\ head\\ without\\ contrast\\:\\ unremarkable\\ \\-\\ no\\ aneurysms\ \(0\)\
\-\ adpkd\\ \\-autosomal\\ dominant\\ polycystic\\ kidney\\ disease\ \(0\)\
\-\ \\â\\€\\¢\\ lymphoma\\ of\\ kidney\ \(0\)\
\-\ \\â\\€\\¢\\ renal\\ cell\\ carcinoma\\ \ \(0\)\
\-\ \\â\\€\\¢\\ tuberous\\ sclerosis\ \(1\)\
\-\ \\â\\€\\¢\\ von\\ hippel\\-lindau\\ syndrome\ \(0\)\
\-\ \\â\\€\\¢\\ multilocular\\ cystic\\ nephroma\ \(0\)\
\-\ \\â\\€\\¢\\ echinococcosis\ \(0\)\
\-\ 44\\ y\\.o\\.\\ woman\\ with\\ abdominal\\ pain\ \(1\)\
\-\ adpkd\\ is\\ a\\ genetic\\ disorder\\ defined\\ by\\ growth\\ of\\ multiple\\ renal\\ cysts\\ that\\ result\\ in\\ kidney\\ destruction\\ and\\ renal\\ failure\\.\\ the\\ hereditary\\ abnormality\\ is\\ a\\ defect\\ in\\ one\\ of\\ two\\ genes\\:\\ polycystin\\ 1\\ pkd1\\)\\ and\\ \\ polycystin\\ 2\\ \\(pkd2\\)\\,\\ which\\ are\\ thought\\ to\\ be\\ important\\ in\\ cell\\-cell\\ and\\ cell\\-matrix\\ interactions\\ involved\\ in\\ tubular\\ epithelial\\ cell\\ growth\\.\\(3\\)\ \(0\)\
\-\ renal\\ manifestations\\ of\\ adpkd\ \(0\)\
\-\ adpkd\\ manifests\\ as\\ progressive\\ renal\\ failure\\ secondary\\ to\\ cyst\\ enlargement\\.\\ volume\\ progression\\ in\\ polycystic\\ kidney\\ disease\\ has\\ been\\ evaluated\\ in\\ a\\ recent\\ study\\ that\\ measured\\ the\\ correlation\\ between\\ mean\\ total\\ kidney\\ volume\\ and\\ cyst\\ volumes\\ as\\ measured\\ by\\ mri\\ over\\ a\\ three\\-year\\ period\\ and\\ iothalamate\\ clearance\\ as\\ a\\ measure\\ of\\ kidney\\ function\\.\\ the\\ study\\ found\\ that\\ a\\ baseline\\ total\\ kidney\\ volume\\ greater\\ than\\ 1500\\ ml\\ is\\ a\\ predictor\\ of\\ declining\\ glomerular\\ filtration\\ rate\\.\\ furthermore\\,\\ growth\\ of\\ kidney\\ size\\ occurs\\ at\\ the\\ same\\ rate\\ bilaterally\\,\\ and\\ is\\ directly\\ proportional\\ to\\ growth\\ of\\ cysts\\.\\(4\\)\\ \\ \ \(0\)\
\-\ renal\\ complications\\ include\\ hypertension\\,\\ uti\\,\\ defects\\ in\\ concentrating\\ ability\\,\\ hematuria\\,\\ nephrolithiasis\\,\\ and\\ possible\\ renal\\ cell\\ carcinoma\\.\\ flank\\ or\\ abdominal\\ pain\\ is\\ possible\\ and\\ can\\ be\\ due\\ to\\ infection\\,\\ nephrolithiasis\\,\\ cyst\\ hemorrhage\\ or\\ torsion\\,\\ and\\ associated\\ liver\\ complications\\ of\\ polycystic\\ liver\\ enlargement\\.\\ \\ proteinuria\\ is\\ not\\ a\\ major\\ feature\\ of\\ adpkd\\.\\ renal\\ cell\\ carcinoma\\ does\\ not\\ occur\\ at\\ increased\\ frequency\\ from\\ that\\ in\\ the\\ general\\ population\\,\\ but\\ is\\ more\\ likely\\ to\\ present\\ with\\ fever\\ and\\ bilateral\\ tumor\\.\\(5\\)\\ \ \(0\)\
\-\ extrarenal\\ manifestations\ \(0\)\
\-\ extrarenal\\ manifestations\\ of\\ adpkd\\ include\\ cerebral\\ aneurysms\\,\\ hepatic\\ cysts\\,\\ cardiac\\ valve\\ disease\\,\\ colonic\\ diverticula\\,\\ and\\ abdominal\\ wall\\ and\\ inguinal\\ hernias\\.\ \(0\)\
\-\ cerebral\\ aneurysms\\ are\\ the\\ most\\ serious\\ complication\\,\\ though\\ rarely\\ manifest\\.\\ the\\ incidence\\ increases\\ with\\ age\\ and\\ is\\ between\\ 4\\ and\\ 10\\%\\;\\ furthermore\\,\\ the\\ risk\\ of\\ rupture\\ of\\ aneurysms\\ \\<\\ 7\\ mm\\ is\\ low\\ in\\ patients\\ with\\ no\\ preceding\\ rupture\\.\\ procedures\\ of\\ choice\\ for\\ screening\\ for\\ cerebral\\ aneurysms\\ are\\ ct\\ angiography\\ and\\ mra\\.\\ however\\,\\ both\\ these\\ tests\\ carry\\ risks\\:\\ gadolinium\\ during\\ mri\\ has\\ a\\ strong\\ association\\ with\\ nephrogenic\\ systemic\\ fibrosis\\ in\\ pkd\\ patients\\ with\\ moderate\\/severe\\ disease\\,\\ especially\\ if\\ they\\ are\\ on\\ dialysis\\.\\ on\\ the\\ other\\ hand\\,\\ cerebral\\ angiography\\ is\\ associated\\ with\\ increased\\ risk\\ of\\ cerebral\\ bleed\\ or\\ stroke\\.\\(6\\)\\ hence\\,\\ due\\ to\\ the\\ low\\ incidence\\ and\\ risk\\ of\\ rupture\\ and\\ adverse\\ effects\\ associated\\ with\\ screening\\,\\ the\\ current\\ recommendation\\ is\\ to\\ screen\\ only\\ in\\ high\\-risk\\ patients\\ \\(including\\ those\\ with\\ family\\ history\\ of\\ aneurysm\\/stroke\\,\\ those\\ with\\ symptoms\\ such\\ as\\ new\\-onset\\ headache\\ or\\ neurologic\\ defect\\,\\(7\\)\\ \\ and\\ those\\ on\\ anticoagulant\\ therapy\\)\\,\\ and\\ perform\\ intermittent\\ follow\\-up\\ imaging\\ in\\ patients\\ with\\ found\\ aneurysms\\ until\\ the\\ stability\\ of\\ the\\ size\\ of\\ the\\ aneurysm\\(s\\)\\ has\\ been\\ determined\\.\\(6\\)\ \(0\)\
\-\ hepatic\\ cysts\\ are\\ common\\ in\\ patients\\ with\\ adpkd\\:\\ \\>80\\%\\ of\\ pts\\ with\\ adpkd\\ have\\ liver\\ cysts\\.7\\ the\\ prevalence\\ and\\ volume\\ of\\ liver\\ cysts\\ has\\ been\\ found\\ to\\ be\\ proportional\\ to\\ the\\ volume\\ of\\ the\\ kidneys\\.\\ however\\,\\ the\\ cysts\\ are\\ usually\\ asymptomatic\\,\\ albeit\\ rarely\\ cause\\ pain\\ and\\/or\\ infection\\.\\ \\(6\\)\ \(0\)\
\-\ other\\ manifestations\\ of\\ adpkd\\ include\\ cardiac\\ complications\\,\\ such\\ as\\ valvular\\ abnormalities\\ \\(especially\\ mild\\ mitral\\ valve\\ prolapsed\\ and\\ aortic\\ regurgitation\\)\\,\\ likely\\ due\\ to\\ the\\ collagen\\ and\\ extracellular\\ matrix\\ defects\\ associated\\ with\\ the\\ disease\\,\\ and\\ colonic\\ diverticula\\ and\\ abdominal\\ wall\\ and\\ inguinal\\ hernias\\.\\(6\\)\ \(0\)\
\-\ screening\ \(214\)\
\-\ screening\\ for\\ kidney\\ cysts\ \(0\)\
\-\ ultrasound\\ is\\ the\\ screening\\ test\\ of\\ choice\\ due\\ to\\ cost\\ and\\ safety\\ considerations\\ 1\\ and\\ can\\ detect\\ cysts\\ \\>\\ 1\\ cm\\.\\ mri\\ can\\ also\\ detect\\ presence\\ of\\ cysts\\ as\\ small\\ as\\ 3\\ mm\\,\\ appearing\\ as\\ \\â\\€\\œblack\\ holes\\ interspersed\\ on\\ a\\ blanket\\ of\\ bright\\ parenchyma\\â\\€\\\\ on\\ t\\Â\\¬1\\ weighted\\ imaging\\ and\\ as\\ bright\\ areas\\ on\\ t2\\ weighted\\ mri\\.\\(7\\)\ \(0\)\
\-\ ultrasound\\ criteria\\ for\\ the\\ diagnosis\\ of\\ pkd\\ in\\ patients\\ with\\ unknown\\ genotype\\ have\\ been\\ proposed\\.\\ diagnosis\\ of\\ pkd\\ can\\ be\\ made\\ if\\ three\\ or\\ more\\ renal\\ cysts\\ are\\ present\\ in\\ 15\\-39\\ yo\\ patients\\,\\ two\\ or\\ more\\ cysts\\ in\\ each\\ kidney\\ in\\ 40\\-59\\ yo\\ patients\\,\\ and\\ four\\ or\\ more\\ cysts\\ in\\ each\\ kidney\\ in\\ patients\\ over\\ 60\\ yo\\.\\ fewer\\ than\\ two\\ cysts\\ in\\ patients\\ over\\ 40\\ yo\\ who\\ are\\ at\\ risk\\ excludes\\ diagnosis\\ of\\ pkd\\.\\(8\\)\\ these\\ criteria\\ have\\ sensitivity\\ close\\ to\\ 100\\%\\ in\\ patients\\ \\&\\#8805\\;30\\ yo\\ and\\ for\\ younger\\ patients\\ with\\ mutation\\ of\\ pkd1\\ as\\ well\\ as\\ 67\\%\\ for\\ younger\\ patients\\ with\\ mutation\\ of\\ pkd2\\.\\ it\\ is\\ important\\ to\\ note\\ that\\ the\\ above\\ criteria\\ are\\ applicable\\ to\\ ultrasound\\ but\\ not\\ ct\\ or\\ mri\\,\\ as\\ these\\ latter\\ modalities\\ have\\ higher\\ sensitivity\\ than\\ does\\ ultrasound\\.\\(1\\)\\ \ \(0\)\
\-\ genetic\\ testing\\ is\\ possible\\ but\\ reserved\\ for\\ inconclusive\\ imaging\\ or\\ testing\\ of\\ a\\ younger\\ patient\\,\\ such\\ as\\ a\\ potential\\ living\\ related\\ kidney\\ donor\\.\\(1\\)\\ \ \(0\)\
\-\ screening\\ for\\ hepatic\\ cysts\ \(0\)\
\-\ different\\ imaging\\ modalities\\ are\\ used\\ to\\ detect\\ complications\\ of\\ liver\\ involvement\\ in\\ adpkd\\.\\ mri\\ detects\\ complicated\\ liver\\ cysts\\,\\ while\\ ct\\ scan\\ can\\ show\\ signs\\ of\\ infection\\,\\ including\\ \\â\\€\\œfluid\\-debris\\ concentrations\\ within\\ cysts\\,\\ cyst\\ wall\\ thickening\\,\\ intracystic\\ gas\\ bubbles\\,\\ and\\ heterogeneous\\ or\\ increased\\ density\\,\\â\\€\\\\ with\\ diagnosis\\ made\\ using\\ radionuclide\\ imaging\\ and\\ 18\\-f\\ fluorodoxyglucose\\ pet\\.\\(1\\)\\ \ \(0\)\
\-\ screening\\ for\\ brain\\ aneurysms\ \(1\)\
\-\ as\\ discussed\\ above\\,\\ screening\\ for\\ brain\\ aneurysms\\ is\\ only\\ done\\ in\\ the\\ select\\ cases\\ of\\ high\\-risk\\ patients\\.\ \(0\)\
\-\ \\ \ \(1082074\)\
\-\ references\ \(24\)\
\-\ 1\\.\\	torres\\,\\ ve\\ et\\ al\\.\\ autosomal\\ dominant\\ polycystic\\ kidney\\ disease\\.\\ lancet\\ 2007\\;\\ 369\\:\\ 1287\\-301\\.\ \(0\)\
\-\ 2\\.\\	polycystic\\ kidney\\ disease\\.\\ torra\\,\\ r\\.\\ emedicine\\.\\ web\\ site\\:\\ http\\:\\/\\/emedicine\\.medscape\\.com\\/article\\/244907\\-overview\\.\\ accessed\\ on\\ 19\\ oct\\ 2009\\.\\ \ \(0\)\
\-\ 3\\.\\	kumar\\ et\\ al\\.\\ robbins\\ and\\ cotran\\ pathologic\\ basis\\ of\\ disease\\,\\ 7th\\ ed\\.\\ philadelphia\\,\\ elsevier\\ inc\\.\\,\\ 2005\\.\ \(0\)\
\-\ 4\\.\\	grantham\\ jj\\ et\\ al\\.\\ volume\\ progression\\ in\\ polycystic\\ kidney\\ disease\\.\\ n\\ eng\\ j\\ med\\ 2006\\;\\ 354\\:\\ 2122\\-2130\\.\\ \ \(0\)\
\-\ 5\\.\\	chapman\\ ab\\ et\\ al\\.\\ renal\\ manifestations\\ of\\ autosomal\\ dominant\\ polycystic\\ kidney\\ disease\\.\\ uptodate\\.\\ web\\ site\\:\\ www\\.uptodate\\.com\\.\\ accessed\\ on\\ 19\\ oct\\ 2009\\.\\ \ \(0\)\
\-\ 6\\.\\	bennett\\,\\ wm\\ and\\ rose\\,\\ bd\\.\\ extrarenal\\ manifestations\\ of\\ autosomal\\ dominant\\ polycystic\\ kidney\\ disease\\.\\ uptodate\\.\\ web\\ site\\:\\ www\\.uptodate\\.com\\.\\ accessed\\ on\\ 19\\ oct\\ 2009\\.\\ \ \(0\)\
\-\ 7\\.\\	grantham\\ jj\\.\\ autosomal\\ dominant\\ polycystic\\ kidney\\ disease\\.\\ n\\ eng\\ j\\ med\\ 2008\\;\\ 359\\:\\ 1477\\-85\\.\\ \ \(0\)\
\-\ 8\\.\\	pei\\ y\\ et\\ al\\.\\ unified\\ criteria\\ for\\ ultrasonographic\\ diagnosis\\ of\\ adpkd\\.\\ j\\ am\\ soc\\ nephrol\\ 2009\\;\\ 20\\:\\ 205\\-212\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ adpkd\\:\\ 0\\.056659558767895336\ \(0\)\
\-\ cysts\\:\\ 0\\.044914594165851016\ \(0\)\
\-\ kidney\\:\\ 0\\.04276787860370969\ \(0\)\
\-\ polycystic\\:\\ 0\\.03590281355521422\ \(0\)\
\-\ aneurysms\\:\\ 0\\.03237025395329163\ \(0\)\
\-\ pkd\\:\\ 0\\.027831155245355954\ \(0\)\
\-\ renal\\:\\ 0\\.026343474461685\ \(0\)\
\-\ patients\\:\\ 0\\.024437288390784816\ \(0\)\
\-\ manifestations\\:\\ 0\\.023035239330947456\ \(0\)\
\-\ screening\\:\\ 0\\.023015213442325787\ \(0\)\
\-\ volume\\:\\ 0\\.019114735268452893\ \(0\)\
\-\ dominant\\:\\ 0\\.017210620077793965\ \(0\)\
\-\ 2009\\:\\ 0\\.017200387037032434\ \(0\)\
\-\ liver\\:\\ 0\\.01627746691067803\ \(0\)\
\-\ extrarenal\\:\\ 0\\.01626584437626958\ \(0\)\
\-\ autosomal\\:\\ 0\\.015609526165930884\ \(0\)\
\-\ as\\:\\ 0\\.015302811829843659\ \(0\)\
\-\ criteria\\:\\ 0\\.014751014041278503\ \(0\)\
\-\ al\\:\\ 0\\.014295823098170039\ \(0\)\
\-\ polycystin\\:\\ 0\\.013915577622677977\ \(0\)\
\-\ pkd1\\:\\ 0\\.013915577622677977\ \(0\)\
\-\ pkd2\\:\\ 0\\.013915577622677977\ \(0\)\
\-\ grantham\\:\\ 0\\.013915577622677977\ \(0\)\
\-\ et\\:\\ 0\\.013801888043102927\ \(0\)\
\-\ oct\\:\\ 0\\.013449149663861126\ \(0\)\
\-\ complications\\:\\ 0\\.013362954992154922\ \(0\)\
\-\ disease\\:\\ 0\\.013228769135428928\ \(0\)\
\-\ accessed\\:\\ 0\\.012983379432812853\ \(0\)\
\-\ eng\\:\\ 0\\.012821422641525734\ \(0\)\
\-\ web\\:\\ 0\\.012594343005130272\ \(0\)\
\-\ detect\\:\\ 0\\.01226029738967667\ \(0\)\
\-\ nephrolithiasis\\:\\ 0\\.011913169984328897\ \(0\)\
\-\ \\)\\:\\ 0\\.01182659158198848\ \(0\)\
\-\ younger\\:\\ 0\\.011807917192132764\ \(0\)\
\-\ growth\\:\\ 0\\.011730550895476873\ \(0\)\
\-\ proportional\\:\\ 0\\.011727267660373493\ \(0\)\
\-\ cerebral\\:\\ 0\\.011682898586282837\ \(0\)\
\-\ \\:\\:\\ 0\\.011597137022792931\ \(0\)\
\-\ \\,\\:\\ 0\\.01153776127697989\ \(0\)\
\-\ \\(\\:\\ 0\\.0114027107536521\ \(0\)\
\-\ www\\.uptodate\\.com\\:\\ 0\\.011375028431779633\ \(0\)\
\-\ 1\\:\\ 0\\.01123384733679396\ \(0\)\
\-\ high\\-risk\\:\\ 0\\.011087228026422168\ \(0\)\
\-\ jj\\:\\ 0\\.010843896250846386\ \(0\)\
\-\ yo\\:\\ 0\\.010147401433712558\ \(0\)\
\-\ progression\\:\\ 0\\.0100659121527198\ \(0\)\
\-\ uptodate\\:\\ 0\\.009993073045269925\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.009894328976138202\ \(0\)\
\-\ risk\\:\\ 0\\.009771765263959231\ \(0\)\
\-\ \\;\\:\\ 0\\.009591576267336671\ \(0\)\
\-\ 19\\:\\ 0\\.009329884216492534\ \(0\)\
\-\ mri\\:\\ 0\\.009297281080890072\ \(0\)\
\-\ those\\:\\ 0\\.009206625269477412\ \(0\)\
\-\ are\\:\\ 0\\.009193953216492516\ \(0\)\
\-\ been\\:\\ 0\\.009174407614301465\ \(0\)\
\-\ j\\:\\ 0\\.009138969296839553\ \(0\)\
\-\ possible\\:\\ 0\\.0090859738559876\ \(0\)\
\-\ cyst\\:\\ 0\\.00906223810586465\ \(0\)\
\-\ hernias\\:\\ 0\\.00883447924088129\ \(0\)\
\-\ or\\:\\ 0\\.00869514620252627\ \(0\)\
\-\ mutation\\:\\ 0\\.008600193518516217\ \(0\)\
\-\ rupture\\:\\ 0\\.00859068496793783\ \(0\)\
\-\ site\\:\\ 0\\.008551330079454703\ \(0\)\
\-\ uti\\:\\ 0\\.008546678835523824\ \(0\)\
\-\ found\\:\\ 0\\.008502054031419454\ \(0\)\
\-\ hepatic\\:\\ 0\\.008449473603329153\ \(0\)\
\-\ such\\:\\ 0\\.008433568397287617\ \(0\)\
\-\ in\\:\\ 0\\.008314862473169987\ \(0\)\
\-\ furthermore\\:\\ 0\\.008258878430166358\ \(0\)\
\-\ diverticula\\:\\ 0\\.008215628273594748\ \(0\)\
\-\ modalities\\:\\ 0\\.008092563488322907\ \(0\)\
\-\ 6\\:\\ 0\\.008057206507892264\ \(0\)\
\-\ ultrasound\\:\\ 0\\.00800354407263237\ \(0\)\
\-\ associated\\:\\ 0\\.007957626526865437\ \(0\)\
\-\ imaging\\:\\ 0\\.007900843821845315\ \(0\)\
\-\ n\\:\\ 0\\.007837996562362178\ \(0\)\
\-\ treatments\\:\\ 0\\.007804763082965442\ \(0\)\
\-\ 7\\:\\ 0\\.007752773982970969\ \(0\)\
\-\ diagnosis\\:\\ 0\\.007743564841280268\ \(0\)\
\-\ med\\:\\ 0\\.007740324259729048\ \(0\)\
\-\ can\\:\\ 0\\.007648864847944237\ \(0\)\
\-\ sensitivity\\:\\ 0\\.007618838796215033\ \(0\)\
\-\ inguinal\\:\\ 0\\.0075898740942920715\ \(0\)\
\-\ mra\\:\\ 0\\.007561431307389658\ \(0\)\
\-\ genetic\\:\\ 0\\.0073755070206392515\ \(0\)\
\-\ colonic\\:\\ 0\\.007350647735764524\ \(0\)\
\-\ measured\\:\\ 0\\.0073261738817219585\ \(0\)\
\-\ have\\:\\ 0\\.007302439141140852\ \(0\)\
\-\ cell\\:\\ 0\\.007287263493548497\ \(0\)\
\-\ due\\:\\ 0\\.007198980751232327\ \(0\)\
\-\ that\\:\\ 0\\.0069896482804679885\ \(0\)\
\-\ choice\\:\\ 0\\.0069787991622637085\ \(0\)\
\-\ each\\:\\ 0\\.0069787991622637085\ \(0\)\
\-\ arbs\\:\\ 0\\.0069577888113389885\ \(0\)\
\-\ echinococcosis\\:\\ 0\\.0069577888113389885\ \(0\)\
\-\ cell\\-cell\\:\\ 0\\.0069577888113389885\ \(0\)\
\-\ cell\\-matrix\\:\\ 0\\.0069577888113389885\ \(0\)\
\-\ three\\-year\\:\\ 0\\.0069577888113389885\ \(0\)\
\-\ iothalamate\\:\\ 0\\.0069577888113389885\ \(0\)\
\-\ moderate\\/severe\\:\\ 0\\.0069577888113389885\ \(0\)\
\-\ aneurysm\\/stroke\\:\\ 0\\.0069577888113389885\ \(0\)\
\-\ cysts\\.7\\:\\ 0\\.0069577888113389885\ \(0\)\
\-\ blanket\\:\\ 0\\.0069577888113389885\ \(0\)\
\-\ t\\Â\\¬1\\:\\ 0\\.0069577888113389885\ \(0\)\
\-\ 15\\-39\\:\\ 0\\.0069577888113389885\ \(0\)\
\-\ 40\\-59\\:\\ 0\\.0069577888113389885\ \(0\)\
\-\ 8805\\:\\ 0\\.0069577888113389885\ \(0\)\
\-\ 18\\-f\\:\\ 0\\.0069577888113389885\ \(0\)\
\-\ fluorodoxyglucose\\:\\ 0\\.0069577888113389885\ \(0\)\
\-\ torres\\:\\ 0\\.0069577888113389885\ \(0\)\
\-\ ve\\:\\ 0\\.0069577888113389885\ \(0\)\
\-\ 1287\\-301\\:\\ 0\\.0069577888113389885\ \(0\)\
\-\ torra\\:\\ 0\\.0069577888113389885\ \(0\)\
\-\ \\/\\/emedicine\\.medscape\\.com\\/article\\/244907\\-overview\\:\\ 0\\.0069577888113389885\ \(0\)\
\-\ 354\\:\\ 0\\.0069577888113389885\ \(0\)\
\-\ 2122\\-2130\\:\\ 0\\.0069577888113389885\ \(0\)\
\-\ 1477\\-85\\:\\ 0\\.0069577888113389885\ \(0\)\
\-\ pei\\:\\ 0\\.0069577888113389885\ \(0\)\
\-\ unified\\:\\ 0\\.0069577888113389885\ \(0\)\
\-\ 205\\-212\\:\\ 0\\.0069577888113389885\ \(0\)\
\-\ for\\:\\ 0\\.006905523112638186\ \(0\)\
\-\ angiography\\:\\ 0\\.006777789813602933\ \(0\)\
\-\ more\\:\\ 0\\.006747202239343855\ \(0\)\
\-\ valve\\:\\ 0\\.006743841581209936\ \(0\)\
\-\ bright\\:\\ 0\\.006743841581209936\ \(0\)\
\-\ abdominal\\:\\ 0\\.006743233585231619\ \(0\)\
\-\ is\\:\\ 0\\.006656954755935978\ \(0\)\
\-\ testing\\:\\ 0\\.0065246838150627914\ \(0\)\
\-\ rarely\\:\\ 0\\.0064672763262374165\ \(0\)\
\-\ interactions\\:\\ 0\\.006410711320762867\ \(0\)\
\-\ prolapsed\\:\\ 0\\.006410711320762867\ \(0\)\
\-\ genotype\\:\\ 0\\.006410711320762867\ \(0\)\
\-\ chapman\\:\\ 0\\.006410711320762867\ \(0\)\
\-\ 359\\:\\ 0\\.006410711320762867\ \(0\)\
\-\ \\%\\:\\ 0\\.006293041936372558\ \(0\)\
\-\ kidneys\\:\\ 0\\.006207918707782364\ \(0\)\
\-\ defects\\:\\ 0\\.006196005202438429\ \(0\)\
\-\ incidence\\:\\ 0\\.0061841809376725915\ \(0\)\
\-\ filtration\\:\\ 0\\.006090691503787204\ \(0\)\
\-\ holes\\:\\ 0\\.006090691503787204\ \(0\)\
\-\ detects\\:\\ 0\\.006090691503787204\ \(0\)\
\-\ fluid\\-debris\\:\\ 0\\.006090691503787204\ \(0\)\
\-\ 369\\:\\ 0\\.006090691503787204\ \(0\)\
\-\ cotran\\:\\ 0\\.006090691503787204\ \(0\)\
\-\ nephrol\\:\\ 0\\.006090691503787204\ \(0\)\
\-\ important\\:\\ 0\\.006059644327617875\ \(0\)\
\-\ infection\\:\\ 0\\.005881649346660159\ \(0\)\
\-\ development\\:\\ 0\\.005874930107592322\ \(0\)\
\-\ weighted\\:\\ 0\\.005865275447738436\ \(0\)\
\-\ glomerular\\:\\ 0\\.005863633830186747\ \(0\)\
\-\ interspersed\\:\\ 0\\.005863633830186747\ \(0\)\
\-\ kumar\\:\\ 0\\.005863633830186747\ \(0\)\
\-\ inc\\.\\:\\ 0\\.005863633830186747\ \(0\)\
\-\ rose\\:\\ 0\\.005863633830186747\ \(0\)\
\-\ wall\\:\\ 0\\.005860676685648176\ \(0\)\
\-\ total\\:\\ 0\\.005808555622598637\ \(0\)\
\-\ two\\:\\ 0\\.005794785882279414\ \(0\)\
\-\ carcinoma\\:\\ 0\\.005734635367046251\ \(0\)\
\-\ function\\:\\ 0\\.005718329239268015\ \(0\)\
\-\ antihypertensive\\:\\ 0\\.005687514215889817\ \(0\)\
\-\ preserving\\:\\ 0\\.005687514215889817\ \(0\)\
\-\ predictor\\:\\ 0\\.005687514215889817\ \(0\)\
\-\ robbins\\:\\ 0\\.005687514215889817\ \(0\)\
\-\ soc\\:\\ 0\\.005687514215889817\ \(0\)\
\-\ and\\:\\ 0\\.005682999391703819\ \(0\)\
\-\ include\\:\\ 0\\.005675975109779685\ \(0\)\
\-\ especially\\:\\ 0\\.005552014297424564\ \(0\)\
\-\ 1500\\:\\ 0\\.005543614013211084\ \(0\)\
\-\ concentrating\\:\\ 0\\.005543614013211084\ \(0\)\
\-\ intracystic\\:\\ 0\\.005543614013211084\ \(0\)\
\-\ lancet\\:\\ 0\\.005543614013211084\ \(0\)\
\-\ bd\\:\\ 0\\.005543614013211084\ \(0\)\
\-\ genes\\:\\ 0\\.005421948125423193\ \(0\)\
\-\ albeit\\:\\ 0\\.005421948125423193\ \(0\)\
\-\ extracellular\\:\\ 0\\.005421948125423193\ \(0\)\
\-\ excludes\\:\\ 0\\.005421948125423193\ \(0\)\
\-\ select\\:\\ 0\\.005421948125423193\ \(0\)\
\-\ made\\:\\ 0\\.005373121345085175\ \(0\)\
\-\ enlargement\\:\\ 0\\.005352120610079077\ \(0\)\
\-\ \\-autosomal\\:\\ 0\\.005316556339610625\ \(0\)\
\-\ nephrogenic\\:\\ 0\\.005316556339610625\ \(0\)\
\-\ than\\:\\ 0\\.005301615283942243\ \(0\)\
\-\ failure\\:\\ 0\\.005284069901864826\ \(0\)\
\-\ these\\:\\ 0\\.005265614898084863\ \(0\)\
\-\ rate\\:\\ 0\\.005257650340135506\ \(0\)\
\-\ declining\\:\\ 0\\.005223594196235421\ \(0\)\
\-\ preceding\\:\\ 0\\.005223594196235421\ \(0\)\
\-\ fewer\\:\\ 0\\.005223594196235421\ \(0\)\
\-\ concentrations\\:\\ 0\\.005223594196235421\ \(0\)\
\-\ bennett\\:\\ 0\\.005223594196235421\ \(0\)\
\-\ over\\:\\ 0\\.005151482060315618\ \(0\)\
\-\ on\\:\\ 0\\.005142082960764682\ \(0\)\
\-\ new\\-onset\\:\\ 0\\.005140436725313695\ \(0\)\
\-\ cost\\:\\ 0\\.005140436725313695\ \(0\)\
\-\ donor\\:\\ 0\\.005140436725313695\ \(0\)\
\-\ ultrasonographic\\:\\ 0\\.005140436725313695\ \(0\)\
\-\ cardiac\\:\\ 0\\.005137863919417475\ \(0\)\
\-\ has\\:\\ 0\\.0050661403961934585\ \(0\)\
\-\ safety\\:\\ 0\\.005065211642595207\ \(0\)\
\-\ to\\:\\ 0\\.005056054953942221\ \(0\)\
\-\ defect\\:\\ 0\\.005049324903393728\ \(0\)\
\-\ \\â\\€\\œ\\:\\ 0\\.005037886215910276\ \(0\)\
\-\ \\â\\€\\\\:\\ 0\\.005009646966106369\ \(0\)\
\-\ inhibitors\\:\\ 0\\.004996536522634962\ \(0\)\
\-\ nephroma\\:\\ 0\\.004996536522634962\ \(0\)\
\-\ proteinuria\\:\\ 0\\.004996536522634962\ \(0\)\
\-\ carry\\:\\ 0\\.004996536522634962\ \(0\)\
\-\ anticoagulant\\:\\ 0\\.004996536522634962\ \(0\)\
\-\ inconclusive\\:\\ 0\\.004996536522634962\ \(0\)\
\-\ mm\\:\\ 0\\.004960055496124713\ \(0\)\
\-\ increased\\:\\ 0\\.0049498455764790585\ \(0\)\
\-\ above\\:\\ 0\\.004943865282758984\ \(0\)\
\-\ elsevier\\:\\ 0\\.004933361536310151\ \(0\)\
\-\ manifests\\:\\ 0\\.0048748706348470715\ \(0\)\
\-\ adverse\\:\\ 0\\.0048748706348470715\ \(0\)\
\-\ including\\:\\ 0\\.004870431951054339\ \(0\)\
\-\ slowing\\:\\ 0\\.004820416908338033\ \(0\)\
\-\ latter\\:\\ 0\\.004820416908338033\ \(0\)\
\-\ radionuclide\\:\\ 0\\.004820416908338033\ \(0\)\
\-\ multilocular\\:\\ 0\\.004769478849034504\ \(0\)\
\-\ emedicine\\:\\ 0\\.004769478849034504\ \(0\)\
\-\ ace\\:\\ 0\\.004721629897324611\ \(0\)\
\-\ clearance\\:\\ 0\\.004721629897324611\ \(0\)\
\-\ recommendation\\:\\ 0\\.004721629897324611\ \(0\)\
\-\ valvular\\:\\ 0\\.004721629897324611\ \(0\)\
\-\ ml\\:\\ 0\\.0046765167056593004\ \(0\)\
\-\ pts\\:\\ 0\\.0046765167056593004\ \(0\)\
\-\ 7th\\:\\ 0\\.0046765167056593004\ \(0\)\
\-\ manifest\\:\\ 0\\.0046338432871350105\ \(0\)\
\-\ bubbles\\:\\ 0\\.0046338432871350105\ \(0\)\
\-\ y\\:\\ 0\\.0046338432871350105\ \(0\)\
\-\ does\\:\\ 0\\.004602401058222583\ \(0\)\
\-\ hippel\\-lindau\\:\\ 0\\.004593359234737575\ \(0\)\
\-\ ab\\:\\ 0\\.004554850817871409\ \(0\)\
\-\ size\\:\\ 0\\.0045222981395087155\ \(0\)\
\-\ volumes\\:\\ 0\\.004518134152019087\ \(0\)\
\-\ reserved\\:\\ 0\\.004483049887953708\ \(0\)\
\-\ living\\:\\ 0\\.004483049887953708\ \(0\)\
\-\ \\>\\:\\ 0\\.004481716676667032\ \(0\)\
\-\ measure\\:\\ 0\\.004449459032058841\ \(0\)\
\-\ feature\\:\\ 0\\.004449459032058841\ \(0\)\
\-\ proposed\\:\\ 0\\.004449459032058841\ \(0\)\
\-\ applicable\\:\\ 0\\.004449459032058841\ \(0\)\
\-\ study\\:\\ 0\\.004438249971365366\ \(0\)\
\-\ sizes\\:\\ 0\\.004417239620440645\ \(0\)\
\-\ hence\\:\\ 0\\.004417239620440645\ \(0\)\
\-\ follow\\-up\\:\\ 0\\.004388377255630216\ \(0\)\
\-\ risks\\:\\ 0\\.004356496888683638\ \(0\)\
\-\ r\\.\\:\\ 0\\.004356496888683638\ \(0\)\
\-\ serious\\:\\ 0\\.00432779314427095\ \(0\)\
\-\ but\\:\\ 0\\.004315319576243578\ \(0\)\
\-\ between\\:\\ 0\\.004275446781727299\ \(0\)\
\-\ wm\\:\\ 0\\.004273339417761912\ \(0\)\
\-\ identification\\:\\ 0\\.004247459526031059\ \(0\)\
\-\ von\\:\\ 0\\.004247459526031059\ \(0\)\
\-\ dialysis\\:\\ 0\\.004222401358458383\ \(0\)\
\-\ mean\\:\\ 0\\.004198114335043424\ \(0\)\
\-\ be\\:\\ 0\\.004160242220501749\ \(0\)\
\-\ prevalence\\:\\ 0\\.004151673529974021\ \(0\)\
\-\ regurgitation\\:\\ 0\\.004151673529974021\ \(0\)\
\-\ mitral\\:\\ 0\\.004129439215083179\ \(0\)\
\-\ epithelial\\:\\ 0\\.004107814136797374\ \(0\)\
\-\ ability\\:\\ 0\\.004107814136797374\ \(0\)\
\-\ target\\:\\ 0\\.004066264228758368\ \(0\)\
\-\ brain\\:\\ 0\\.004058960573485023\ \(0\)\
\-\ only\\:\\ 0\\.004055898434861776\ \(0\)\
\-\ 67\\:\\ 0\\.0040462817441614535\ \(0\)\
\-\ basis\\:\\ 0\\.0040462817441614535\ \(0\)\
\-\ of\\:\\ 0\\.004045909419977499\ \(0\)\
\-\ baseline\\:\\ 0\\.003989201506134914\ \(0\)\
\-\ varying\\:\\ 0\\.00395331960078625\ \(0\)\
\-\ increases\\:\\ 0\\.00395331960078625\ \(0\)\
\-\ effects\\:\\ 0\\.003935972397377588\ \(0\)\
\-\ strong\\:\\ 0\\.003918998281181089\ \(0\)\
\-\ screen\\:\\ 0\\.003918998281181089\ \(0\)\
\-\ 2008\\:\\ 0\\.003902381541482721\ \(0\)\
\-\ considerations\\:\\ 0\\.0038861074395073964\ \(0\)\
\-\ black\\:\\ 0\\.0038861074395073964\ \(0\)\
\-\ 2006\\:\\ 0\\.0038861074395073964\ \(0\)\
\-\ 1\\-2\\:\\ 0\\.003870162129864524\ \(0\)\
\-\ hereditary\\:\\ 0\\.003870162129864524\ \(0\)\
\-\ perform\\:\\ 0\\.003870162129864524\ \(0\)\
\-\ bleed\\:\\ 0\\.0038545325897728273\ \(0\)\
\-\ collagen\\:\\ 0\\.0038392065551579087\ \(0\)\
\-\ 2007\\:\\ 0\\.0038094193981075167\ \(0\)\
\-\ likely\\:\\ 0\\.003804719756804509\ \(0\)\
\-\ philadelphia\\:\\ 0\\.003780715653694829\ \(0\)\
\-\ ct\\:\\ 0\\.0037736500501721953\ \(0\)\
\-\ torsion\\:\\ 0\\.0037667459795832268\ \(0\)\
\-\ stability\\:\\ 0\\.0037667459795832268\ \(0\)\
\-\ matrix\\:\\ 0\\.0037667459795832268\ \(0\)\
\-\ 8\\.\\:\\ 0\\.0037667459795832268\ \(0\)\
\-\ 4\\:\\ 0\\.003758440260740403\ \(0\)\
\-\ a\\:\\ 0\\.0037562727875479207\ \(0\)\
\-\ however\\:\\ 0\\.003755908532907767\ \(0\)\
\-\ low\\:\\ 0\\.0037508572263084444\ \(0\)\
\-\ tuberous\\:\\ 0\\.0037132159114389796\ \(0\)\
\-\ correlation\\:\\ 0\\.0037132159114389796\ \(0\)\
\-\ directly\\:\\ 0\\.0037003820354549384\ \(0\)\
\-\ discussed\\:\\ 0\\.0036877535103196257\ \(0\)\
\-\ if\\:\\ 0\\.00366021062948798\ \(0\)\
\-\ slow\\:\\ 0\\.0036510368444673024\ \(0\)\
\-\ procedures\\:\\ 0\\.0036510368444673024\ \(0\)\
\-\ 2005\\:\\ 0\\.003639167959412417\ \(0\)\
\-\ protocol\\:\\ 0\\.0036274749161723688\ \(0\)\
\-\ therapy\\:\\ 0\\.0036063785260309596\ \(0\)\
\-\ 7\\.\\:\\ 0\\.0035934005895226382\ \(0\)\
\-\ every\\:\\ 0\\.0035823617245070586\ \(0\)\
\-\ frequency\\:\\ 0\\.0035607366462212533\ \(0\)\
\-\ pet\\:\\ 0\\.0035396883059827682\ \(0\)\
\-\ tests\\:\\ 0\\.0035293709566794115\ \(0\)\
\-\ population\\:\\ 0\\.0035191867381822468\ \(0\)\
\-\ stroke\\:\\ 0\\.0035191867381822468\ \(0\)\
\-\ determined\\:\\ 0\\.0035191867381822468\ \(0\)\
\-\ complicated\\:\\ 0\\.0034992042535853325\ \(0\)\
\-\ hypertrophy\\:\\ 0\\.003470148236913891\ \(0\)\
\-\ am\\:\\ 0\\.003470148236913891\ \(0\)\
\-\ 44\\:\\ 0\\.003460695836719167\ \(0\)\
\-\ 100\\:\\ 0\\.003406242110210129\ \(0\)\
\-\ stone\\:\\ 0\\.0033553040509066\ \(0\)\
\-\ different\\:\\ 0\\.0033390299489312754\ \(0\)\
\-\ destruction\\:\\ 0\\.0033310170274916404\ \(0\)\
\-\ complication\\:\\ 0\\.0033074550991967063\ \(0\)\
\-\ higher\\:\\ 0\\.0033074550991967063\ \(0\)\
\-\ close\\:\\ 0\\.0032921290645817882\ \(0\)\
\-\ association\\:\\ 0\\.0032770949722607983\ \(0\)\
\-\ 6\\.\\:\\ 0\\.0032770949722607983\ \(0\)\
\-\ bilateral\\:\\ 0\\.0032735875758712614\ \(0\)\
\-\ potential\\:\\ 0\\.0032478595565699144\ \(0\)\
\-\ systemic\\:\\ 0\\.0032266224193008347\ \(0\)\
\-\ gas\\:\\ 0\\.003212775292504537\ \(0\)\
\-\ hematuria\\:\\ 0\\.003199166921206584\ \(0\)\
\-\ gadolinium\\:\\ 0\\.003199166921206584\ \(0\)\
\-\ flank\\:\\ 0\\.003172634473851426\ \(0\)\
\-\ 80\\:\\ 0\\.003172634473851426\ \(0\)\
\-\ current\\:\\ 0\\.0031596953974696767\ \(0\)\
\-\ 3\\:\\ 0\\.0031586038306338432\ \(0\)\
\-\ period\\:\\ 0\\.003153304544878817\ \(0\)\
\-\ major\\:\\ 0\\.003153304544878817\ \(0\)\
\-\ tubular\\:\\ 0\\.003140676019743505\ \(0\)\
\-\ though\\:\\ 0\\.003128246377306141\ \(0\)\
\-\ other\\:\\ 0\\.0031091374091593506\ \(0\)\
\-\ small\\:\\ 0\\.0031074590124405975\ \(0\)\
\-\ thought\\:\\ 0\\.003103959353891182\ \(0\)\
\-\ evaluated\\:\\ 0\\.0030920904688362958\ \(0\)\
\-\ present\\:\\ 0\\.0030465805113365127\ \(0\)\
\-\ disorder\\:\\ 0\\.0030298221638089375\ \(0\)\
\-\ numerous\\:\\ 0\\.0030243976339843423\ \(0\)\
\-\ ventricular\\:\\ 0\\.0030136591556451328\ \(0\)\
\-\ fibrosis\\:\\ 0\\.0030030648223127406\ \(0\)\
\-\ appearing\\:\\ 0\\.0029978205107747224\ \(0\)\
\-\ until\\:\\ 0\\.0029620547679080752\ \(0\)\
\-\ pathologic\\:\\ 0\\.0029521267630092116\ \(0\)\
\-\ 60\\:\\ 0\\.0029423220905557333\ \(0\)\
\-\ four\\:\\ 0\\.0029278397395942524\ \(0\)\
\-\ using\\:\\ 0\\.0029278397395942524\ \(0\)\
\-\ not\\:\\ 0\\.0029238011169895866\ \(0\)\
\-\ 5\\.\\:\\ 0\\.002908934261281314\ \(0\)\
\-\ 2\\:\\ 0\\.0029046637671831825\ \(0\)\
\-\ intermittent\\:\\ 0\\.0028950465249826716\ \(0\)\
\-\ test\\:\\ 0\\.0028813989345248493\ \(0\)\
\-\ parenchyma\\:\\ 0\\.0028724299063872683\ \(0\)\
\-\ and\\/or\\:\\ 0\\.002850443359818234\ \(0\)\
\-\ ed\\:\\ 0\\.002850443359818234\ \(0\)\
\-\ defined\\:\\ 0\\.0028418174162253454\ \(0\)\
\-\ general\\:\\ 0\\.0028418174162253454\ \(0\)\
\-\ 40\\:\\ 0\\.0028375395413482033\ \(0\)\
\-\ the\\:\\ 0\\.002837001896049148\ \(0\)\
\-\ us\\:\\ 0\\.00282905272858083\ \(0\)\
\-\ involved\\:\\ 0\\.00282905272858083\ \(0\)\
\-\ neurologic\\:\\ 0\\.0028164912011097174\ \(0\)\
\-\ references\\:\\ 0\\.0028041264680833565\ \(0\)\
\-\ done\\:\\ 0\\.0027959896333091963\ \(0\)\
\-\ related\\:\\ 0\\.0027839395369155195\ \(0\)\
\-\ same\\:\\ 0\\.002779963377460147\ \(0\)\
\-\ hand\\:\\ 0\\.0027720706518606334\ \(0\)\
\-\ occurs\\:\\ 0\\.0027681536910539014\ \(0\)\
\-\ family\\:\\ 0\\.0027642560733423132\ \(0\)\
\-\ at\\:\\ 0\\.0027413492174387525\ \(0\)\
\-\ aortic\\:\\ 0\\.002730017481684677\ \(0\)\
\-\ includes\\:\\ 0\\.002718926910685742\ \(0\)\
\-\ progressive\\:\\ 0\\.002665697801928416\ \(0\)\
\-\ aneurysm\\:\\ 0\\.002665697801928416\ \(0\)\
\-\ hypertension\\:\\ 0\\.002658864287529746\ \(0\)\
\-\ 4\\.\\:\\ 0\\.002655469589898025\ \(0\)\
\-\ pressure\\:\\ 0\\.0026487236857319174\ \(0\)\
\-\ \\#\\:\\ 0\\.00264537223278681\ \(0\)\
\-\ unknown\\:\\ 0\\.002632106946033549\ \(0\)\
\-\ \\<\\:\\ 0\\.0026030509293621077\ \(0\)\
\-\ note\\:\\ 0\\.0026030509293621077\ \(0\)\
\-\ 30\\:\\ 0\\.0025935985291673834\ \(0\)\
\-\ result\\:\\ 0\\.002587359239895787\ \(0\)\
\-\ used\\:\\ 0\\.002587359239895787\ \(0\)\
\-\ http\\:\\ 0\\.0025538978673877474\ \(0\)\
\-\ greater\\:\\ 0\\.002533319935020127\ \(0\)\
\-\ occur\\:\\ 0\\.002530423542842572\ \(0\)\
\-\ 8\\:\\ 0\\.002521797599249683\ \(0\)\
\-\ calcifications\\:\\ 0\\.002507627272796174\ \(0\)\
\-\ abnormality\\:\\ 0\\.0024882067433548163\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.0024800277480623565\ \(0\)\
\-\ abnormalities\\:\\ 0\\.0024773201434082214\ \(0\)\
\-\ involvement\\:\\ 0\\.002471932641379492\ \(0\)\
\-\ pain\\:\\ 0\\.0024710532774997666\ \(0\)\
\-\ presence\\:\\ 0\\.0024481338740782394\ \(0\)\
\-\ they\\:\\ 0\\.0024301074400057666\ \(0\)\
\-\ 20\\:\\ 0\\.0024250317570300045\ \(0\)\
\-\ sclerosis\\:\\ 0\\.0024225061037303434\ \(0\)\
\-\ signs\\:\\ 0\\.002373619521693808\ \(0\)\
\-\ \\&\\:\\ 0\\.0023688933639632453\ \(0\)\
\-\ headache\\:\\ 0\\.0023164841654031553\ \(0\)\
\-\ 3\\.\\:\\ 0\\.0023077144531497454\ \(0\)\
\-\ elevated\\:\\ 0\\.002288331776921123\ \(0\)\
\-\ thickening\\:\\ 0\\.0022862072373270336\ \(0\)\
\-\ fever\\:\\ 0\\.0022819752380047087\ \(0\)\
\-\ cause\\:\\ 0\\.0022819752380047087\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.00227986771743969\ \(0\)\
\-\ 10\\:\\ 0\\.002273578712191721\ \(0\)\
\-\ three\\:\\ 0\\.002273578712191721\ \(0\)\
\-\ areas\\:\\ 0\\.0022694137105335964\ \(0\)\
\-\ available\\:\\ 0\\.002267339422920124\ \(0\)\
\-\ recent\\:\\ 0\\.002267339422920124\ \(0\)\
\-\ cases\\:\\ 0\\.002246890973939331\ \(0\)\
\-\ by\\:\\ 0\\.0022460472032279004\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.0022448749677790336\ \(0\)\
\-\ unremarkable\\:\\ 0\\.002232885886884026\ \(0\)\
\-\ density\\:\\ 0\\.002219124985682683\ \(0\)\
\-\ bilaterally\\:\\ 0\\.0022152369680535937\ \(0\)\
\-\ 2\\.\\:\\ 0\\.002144786220836826\ \(0\)\
\-\ while\\:\\ 0\\.0021220593842559694\ \(0\)\
\-\ 1\\.\\:\\ 0\\.0021067002101796376\ \(0\)\
\-\ show\\:\\ 0\\.002070367746244377\ \(0\)\
\-\ during\\:\\ 0\\.002063937845243732\ \(0\)\
\-\ age\\:\\ 0\\.0020528100438392317\ \(0\)\
\-\ usually\\:\\ 0\\.0020480885981584524\ \(0\)\
\-\ no\\:\\ 0\\.0020373578943262876\ \(0\)\
\-\ years\\:\\ 0\\.001980460250211904\ \(0\)\
\-\ 5\\:\\ 0\\.0019732915725684005\ \(0\)\
\-\ y\\.o\\:\\ 0\\.001946629386414128\ \(0\)\
\-\ cystic\\:\\ 0\\.0019452507555262498\ \(0\)\
\-\ s\\:\\ 0\\.0019343075509980956\ \(0\)\
\-\ syndrome\\:\\ 0\\.0019288923257574123\ \(0\)\
\-\ lymphoma\\:\\ 0\\.0019275443049640772\ \(0\)\
\-\ head\\:\\ 0\\.001912866069908363\ \(0\)\
\-\ t2\\:\\ 0\\.0019089098411604988\ \(0\)\
\-\ scan\\:\\ 0\\.0018881384849510484\ \(0\)\
\-\ secondary\\:\\ 0\\.0018855800840637787\ \(0\)\
\-\ blood\\:\\ 0\\.0018408927170554849\ \(0\)\
\-\ one\\:\\ 0\\.0018277280057700427\ \(0\)\
\-\ \\.\\:\\ 0\\.0018212074556649628\ \(0\)\
\-\ cm\\:\\ 0\\.0018089629974877553\ \(0\)\
\-\ mild\\:\\ 0\\.0017760485034973457\ \(0\)\
\-\ common\\:\\ 0\\.0017650096384817656\ \(0\)\
\-\ who\\:\\ 0\\.0017584596757235218\ \(0\)\
\-\ both\\:\\ 0\\.0017223362199574755\ \(0\)\
\-\ symptoms\\:\\ 0\\.0016808662011824301\ \(0\)\
\-\ none\\:\\ 0\\.0016730224995327597\ \(0\)\
\-\ with\\:\\ 0\\.0016622534882541557\ \(0\)\
\-\ without\\:\\ 0\\.0015880135488225415\ \(0\)\
\-\ tumor\\:\\ 0\\.0015724011851703324\ \(0\)\
\-\ woman\\:\\ 0\\.001557934449478221\ \(0\)\
\-\ most\\:\\ 0\\.001557091666715135\ \(0\)\
\-\ well\\:\\ 0\\.0015257150378600245\ \(0\)\
\-\ it\\:\\ 0\\.0015160602877135095\ \(0\)\
\-\ contrast\\:\\ 0\\.001509688782010975\ \(0\)\
\-\ \\-\\:\\ 0\\.0014457209618850542\ \(0\)\
\-\ multiple\\:\\ 0\\.0014205256538905042\ \(0\)\
\-\ treatment\\:\\ 0\\.0013651278292035414\ \(0\)\
\-\ also\\:\\ 0\\.001329612938966181\ \(0\)\
\-\ within\\:\\ 0\\.0012866072678658891\ \(0\)\
\-\ which\\:\\ 0\\.0012589933600967236\ \(0\)\
\-\ from\\:\\ 0\\.0009995546275881708\ \(0\)\
\-\ history\\:\\ 0\\.0009315031868248488\ \(0\)\
\-\ left\\:\\ 0\\.0007546213648562863\ \(0\)\
\-\ patient\\:\\ 0\\.0006760788720729186\ \(0\)\
